← Back to searchRecruitingRecruiting
The Efficacy of Fluticasone Furoate/Vilanterol/Umeclidinium Compared With Vilanterol/Umeclidinium in Reducing Air Trapping and Airway and Blood Cytokine Levels in COPD
NCT06474039 · Mahidol University
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
About this study
This study aims to demonstrate the effects of triple therapy (ICS/LABA/LAMA) and dual bronchodilators (LAMA/LABA) on air trapping in the lungs' COPD patients and inflammatory mediators
Eligibility criteria
Inclusion Criteria:
* Patients who have met the criteria for COPD GOLD B defined by an exacerbation not more than 1 time in the last year prior to the study enrollment. These patients will be recruited in sequential sequence.
* Patients with COPD GOLD B are previously treated with either LAMA or LAMA/LABA or short-acting bronchodilators
* Patients who are able to provide informed consent.
Exclusion Criteria:
* \- Concomitant with active and old pulmonary TB, lung cancer, bronchiectasis, lung fibrosis, destroyed lung, other malignancy, active heart diseases.
* Receiving long-term treatment with immunosuppressive drugs and systemic corticosteroids
* Being treated with triple therapy (ICS/LABA/LAMA)
* Being in terminally ill conditions
Study design
Enrollment target: 50 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2024-10-01
Estimated completion: 2026-12
Last updated: 2025-05-06
Interventions
Drug: Trelegy or Anoro
Primary outcomes
- • Changes in lung volume (4 weeks)
Sponsor
Mahidol University · other
Contacts & investigators
Contactkittipong maneechotesuwan, MD, PhD. · contact · kittipong.man@mahidol.ac.th · 0894996858
InvestigatorKittipong Maneechotesuwan, MD,PhD · principal_investigator, Siriraj Hospital
All locations (1)
Division of Respiratory Disease and TB, Siriraj HospitalRecruiting
Bangkoknoi, BKK, Thailand